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Saxton SN, Whitley AS, Potter RJ, Withers SB, Grencis R,
Heagerty AM. Interleukin-33 rescues perivascular adipose tissue anti-
contractile function in obesity. Am J Physiol Heart Circ Physiol 319:
H1387–H1397, 2020. First published October 9, 2020; doi:10.1152/
ajpheart.00491.2020.—Perivascular adipose tissue (PVAT) depots are
metabolically active and play a major vasodilator role in healthy lean
individuals. In obesity, they become inflamed and eosinophil-depleted
and the anticontractile function is lost with the development of diabe-
tes and hypertension. Moreover, eosinophil-deficient DdblGATA-1
mice lack PVAT anticontractile function and exhibit hypertension.
Here, we have investigated the effects of inducing eosinophilia on
PVAT function in health and obesity. Control, obese, and DdblGATA-
1 mice were administered intraperitoneal injections of interleukin-33
(IL-33) for 5 days. Conscious restrained blood pressure was measured,
and blood was collected for glucose and plasma measurements. Wire
myography was used to assess the contractility of mesenteric resist-
ance arteries. IL-33 injections induced a hypereosinophilic phenotype.
Obese animals had significant elevations in blood pressure, blood glu-
cose, and plasma insulin, which were normalized with IL-33. Blood
glucose and insulin levels were also lowered in lean treated mice. In
arteries from control mice, PVAT exerted an anticontractile effect on
the vessels, which was enhanced with IL-33 treatment. In obese mice,
loss of PVAT anticontractile function was rescued by IL-33. Exogen-
ous application of IL-33 to isolated arteries induced a rapidly decaying
endothelium-dependent vasodilation. The therapeutic effects were not
seen in IL-33-treated DdblGATA-1 mice, thereby confirming that the
eosinophil is crucial. In conclusion, IL-33 treatment restored PVAT
anticontractile function in obesity and reversed development of hyper-
tension, hyperglycemia, and hyperinsulinemia. These data suggest that
targeting eosinophil numbers in PVAT offers a novel approach to the
treatment of hypertension and type 2 diabetes in obesity.
NEW & NOTEWORTHY In this study, we have shown that
administering IL-33 to obese mice will restore PVAT anticontrac-
tile function, and this is accompanied by normalized blood pressure,
blood glucose, and plasma insulin. Moreover, the PVAT effect is
enhanced in control mice given IL-33. IL-33 induced a hypereosi-
nophilic phenotype in our mice, and the effects of IL-33 on PVAT
function, blood pressure, and blood glucose are absent in eosino-
phil-deficient mice, suggesting that the effects of IL-33 are medi-
ated via eosinophils.
adipose tissue; diabetes mellitus; hypereosinophilia; hypertension;
obesity
INTRODUCTION
The majority of peripheral blood vessels are invested in a
layer of perivascular adipose tissue (PVAT) (1, 19, 24). In
healthy lean individuals, it exerts an anticontractile effect on
vascular tone via endocrine and paracrine mechanisms, thereby
having an important hemodynamic influence on glucose uptake
and blood pressure. In addition to adipocytes, nerves, and stem
cells, PVAT contains a diverse and highly plastic immune cell
population (2, 4, 46). We have shown previously that the PVAT
anticontractile effect is lost in obesity, which may be contribut-
ing to the development of hypertension and type II diabetes
(T2D) in this condition (2, 7, 19, 56). Interestingly, not all obese
patients are hypertensive, but a common feature between obese
hypertensives and lean hypertensive patients is inflammation of
adipose tissues (28, 40).
In obesity, excess caloric intake results in hypertrophic expan-
sion of adipocytes, without an accompanying increase in angio-
genesis (7, 9, 18). This results in areas of local hypoxia and
inflammation, and indeed, the loss of PVAT function in obesity
can be replicated in healthy isolated vessels incubated under
hypoxic conditions (19). Previously, we have found that eosino-
phil numbers in PVAT are reduced in a mouse model of obesity
(7). In addition, the PVAT anticontractile effect is lost in the eo-
sinophil-deficient DdblGATA-1 mouse and can be rescued by
eosinophil reconstitution (52). Moreover, this mouse model is
hypertensive and hyperglycemic. These studies indicate an inter-
esting avenue of research, whereby the manipulation of eosino-
phil number in PVAT could present a therapeutic target in
obesity. This proposal is supported by the low incidence of car-
diovascular disease in countries where helminth infections are
prevalent (5, 26).
Numerous studies are beginning to emerge which explore the
therapeutic potential of helminth infection in inflammatory dis-
eases, such as asthma and inflammatory bowel disease (14, 30).
Of particular interest in the context of this study, Wu et al. (54)
demonstrated that helminth-induced eosinophilia improves glu-
cose tolerance in a mouse model of obesity. Interleukin-33 (IL-
33) has been shown to directly activate eosinophils and play a
role in eosinophil development (25). IL-33, which is a member of
the interleukin-1 cytokine family, has been shown to drive the
Th2 pro-inflammatory immune response (35, 44). Therefore, the
present study was designed to examine the effects of IL-33 in a
mouse model of obesity. We tested the hypothesis that IL-33Correspondence: A. M. Heagerty (tony.heagerty@manchester.ac.uk).
http://www.ajpheart.org Copyright© 2020 the Authors. Licensed under Creative Commons Attribution CC-BY 4.0. Published by the American Physiological Society. H1387
Am J Physiol Heart Circ Physiol 319: H1387–H1397, 2020.
First published October 9, 2020; doi:10.1152/ajpheart.00491.2020.
Downloaded from journals.physiology.org/journal/ajpheart at Univ of Salford Lib (146.087.136.100) on December 11, 2020.
injections would restore depleted eosinophil numbers in obese
PVAT and rescue the PVAT anticontractile effect. We antici-
pated that the restoration of the PVAT anticontractile effect
would be accompanied by reversal of hypertension and T2D in
our obese model. We report that both effects were observed, with
evidence of benefits also in lean chow-fed mice.
MATERIALS AND METHODS
Animal care and handling. All animal procedures were performed
in accordance with the UK Animals (Scientific Procedures) Act 1986
under the appropriate Home Office License (P3A97F3D1), with ethical
approval from the University of Manchester Ethics Committee. Male
C57BL/6J mice (Charles River Laboratories, UK) were housed under a
12-h light/dark cycle and provided with food and water ad libitum.
Mice were euthanized at 18–20 wk old by CO2 asphyxiation followed
by exsanguination. Animals were randomly assigned to experimental
groups. Control mice were fed a standard chow diet (7.42% fat, Cat
No. BK001, SDS Diets, UK). Obese mice were fed from 8 wk old with
a 60% kcal from fat diet (Cat No. 824054, SDS Diets, UK) until eutha-
nized. The effects of IL-33 were investigated in both control and obese
mice by daily intraperitoneal injection of 0.1 μg of IL-33 (12) (Bio-
Techne) reconstituted in saline (0.9% NaCl, Baxter Healthcare Ltd, UK)
for five consecutive days before euthanasia. The last dosage was admin-
istered 24 h before euthanasia. To confirm the effects of IL-33 are medi-
ated via eosinophils, IL-33 injections were also administered to the
eosinophil-deficient DdblGATA-1 mouse [C.129S1(B6)-Gata1tm6Sho/
J, RRID: IMSR_JAX:005653, Jackson Laboratories]. Endothelial
nitric oxide synthase knockout mice (eNOS/; strain B6.129P2-
Nos3tm1Unc/J, RRID: IMSR_JAX:002684) were kindly provided by
Dr. Elizabeth Cottrell. There were eight mice in control, obese, control +
IL-33, obese + IL-33, and eNOS/ groups, and seven mice in the
DdblGATA-1 + IL-33 group.
Immediately before euthanasia, conscious mice were restrained, and
systolic and diastolic blood pressure was measured using a CODA tail-
cuff blood pressure monitoring system (Kent Scientific). Although not
the gold standard, this method has been validated as showing good agree-
ment with radiotelemetry recordings (13). Mixed blood samples were
taken upon exsanguination, and blood glucose concentration was meas-
ured immediately by the application of a small drop of blood to an auto-
matic blood glucose system (Contour; Bayer Consumer Care AG, Basel,
Switzerland). All remaining blood was collected in BD Vacutainer blood
collection tubes coated with the anticoagulant K2EDTA (Thermo Fisher
Scientific, UK). Plasma was retrieved by centrifuging blood samples at
3,000 g for 10 min at 4C and stored at80C until required.
Immediately following euthanasia, the body weights of the mice
were recorded. The spleen, epididymal fat pads, and mesenteric beds
were dissected out and placed in ice-cold physiological salt solution
(PSS) (119 mM NaCl, 4.7 mM KCl, 1.17 mM MgSO4, 25 mM
NaHCO3, 1.17 mM KH2PO4, 0.03 mMK2EDTA, 5.5 mM glucose, and
1.6 mM CaCl2; Thermo Fisher Scientific, UK) until required. Dry
weights of spleens were recorded.
Eosinophil cationic protein, adiponectin, and insulin assays. The
concentration of plasma insulin, adiponectin, and eosinophil cationic
protein was measured using commercially available ELISA kits
according to manufacturer instructions (Table 1). All samples and
standards were measured in duplicate, and the optical density of the
zero standard was subtracted from each value. Standard curves were fit-
ted using nonlinear regression analysis with a sigmoidal four-parameter
logistic curve to interpolate values.
Wire myography. Second-order mesenteric artery segments (<250
mm) with or without PVAT intact were isolated from the mesenteric
bed by fine dissection in ice-cold PSS. Arteries were mounted onto 40-
μm-diameter wires using a wire myograph system (Danish MyoTech,
Denmark). Mounted arteries were allowed to equilibrate for 30 min in
the myograph at 37C in PSS perfused with 95% air-5% CO2 to main-
tain pH 7.4. Vessel wall tension was normalized according to a standar-
dized procedure (36), and the arteries were allowed to equilibrate for a
further 30 min. Vessels were subjected to 60 mM high [K+]PSS
(KPSS) (63.7 mM NaCl, 60 mM KCl, 1.17 mM MgSO4, 25 mM
NaHCO3, 1.17 mMKH2PO4, 0.03 mM K2EDTA, 5.5 mM glucose, and
1.6 mM CaCl2; Thermo Fisher Scientific, UK) to establish a maximal
constriction response. The KPSS was washed out and replaced with
fresh PSS. Endothelial integrity was tested by preconstricting with 1 
105 M noradrenaline (NA) and applying 1  107 M acetylcholine
(ACh) (both obtained from Sigma-Aldrich, UK, and dissolved in PSS).
Cumulative concentration-response curves were generated using
increasing doses of NA (1  109–3  105 M), with traces continu-
ously generated using LabChart 7 (ADInstruments, UK) in arteries from
control, obese, control + IL-33, obese + IL-33, and the DdblGATA-1 +
IL-33 mice. An example trace of a NA concentration response performed
in a control -PVAT vessel is given in Supplemental Fig. S1 (see https://
doi.org/10.6084/m9.figshare.12962774).
To determine whether IL-33 has a direct effect on vasculature con-
tractility, arteries from control and eNOS/ mice were first precon-
stricted with 1  105 M NA, and once stabilized, 3 ng/mL of IL-33
was added directly to the myograph bath. To determine the role of the
endothelium, arteries from control mice with and without endothelium
were used. To remove the endothelium, equine hair is inserted into the
lumen for mechanical removal. Endothelial integrity was tested as
described above. Vessels with less than a 20% relaxation in response to
ACh were considered to be endothelium denuded.
Immunohistochemistry. PVAT samples (n = 5) were fixed in 4%
ice-cold paraformaldehyde for 1 h. Samples were washed in 0.1 M
phosphate buffer solution before embedding in KP-CryoCompound
(Klinipath BV, The Netherlands). Samples were stored at 80C until
sectioned using a Leica CM 3050 cryostat (12-mm slices, Leica
Microsystems, Germany). Heat-induced antigen retrieval was per-
formed in a citrate buffer for 10 min at 95C, followed by incubation
with 3% hydrogen peroxide. Sections were incubated with 10% goat se-
rum at room temperature for 1 h in combination with Triton X-100
(0.1%). Samples were incubated with the primary polyclonal antibody
for eosinophil peroxidase (10 mg/mL, Abcam, UK; ab65319, RRID:
AB_10712964) overnight at 4C. Slides were incubated for 1 h with a
biotinylated goat antirabbit secondary antibody (2 mg/mL, Abcam, UK;
Cat No. ab6720, RRID: AB_954902) at room temperature. Vectastain
ABC complex (Vector Laboratories, UK) followed by the addition of
3,30-diaminobenzidine (DAB) solution (Vector Laboratories, UK) was
used for the detection of antibody binding. Positive controls were con-
ducted in sections of mouse spleen (Supplemental Fig. S2A, see https://
doi.org/10.6084/m9.figshare.12497930). Negative controls were con-
ducted in PVAT (Supplemental Fig. S2B). These were incubated with
phosphate buffer solution in place of the primary antibody, and incuba-
tion with the secondary antibody and detection methods were con-
ducted as normal. Images were captured using a color camera (Leica
Table 1. Kits and suppliers
Antigen Name of Kit Supplier Catalogue No. Sample Dilution
Adiponectin Adiponectin mouse ELISA kit Life Technologies Ltd KMP0041 1 in 20,000
Eosinophil cationic protein Mouse eosinophil cationic protein
(ECP) ELISA kit
Cusabio Technology LLC CSB-E11799M Control and obese: none
IL-33 injected control and obese: 1 in 4
Insulin Insulin mouse ELISA kit Invitrogen EMINS 1 in 2
H1388 EFFECTS OF IL-33 ON OBESE PVAT
AJP-Heart Circ Physiol  doi:10.1152/ajpheart.00491.2020  www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart at Univ of Salford Lib (146.087.136.100) on December 11, 2020.
DFC450, Leica Microsystems, Germany) mounted on a microscope
(Leica DM5000, Leica Microsystems, Germany).
Statistics. All data are reported as means ± standard error (SE).
Normal distribution was confirmed using Shapiro–Wilk normality test,
supported by skewness and kurtosis coefficients (using an acceptable
range of ±2). Body, epididymal fat pad and spleen weights, blood pres-
sure, blood glucose, plasma insulin, plasma adiponectin, and plasma
eosinophil cationic protein were analyzed using one-way analysis of
variance (ANOVA) with a Tukey’s post hoc test. Consistent with pre-
vious studies (17, 19, 43), vessel contractility ± PVAT was expressed
as a percentage of the maximum contraction evoked by KPSS and
these data were analyzed by two-way ANOVA with a Bonferroni
post hoc test. Relaxation in response to IL-33 or ACh was expressed
as a percentage of the preconstriction elicited with NA and was ana-
lyzed with a one-way ANOVA followed by Tukey’s post hoc test or
an unpaired t test, respectively. Statistical analysis was carried out
using GraphPad Prism 8.0, and a P value <0.05 was considered to be
significant.
RESULTS
IL-33 injections induce eosinophilia and splenomegaly.
Following euthanasia body, epididymal fat pads and spleen
weights of all mice were recorded (Fig. 1, A–C). High-fat feed-
ing induced significant elevations in body weight and epididy-
mal fat pad weight (body weights: control vs. obese P < 0.01,
control + IL-33 vs. obese + IL-33 P < 0.0001; epididymal fat
pad weights: control vs. obese P < 0.0001, control + IL-33 vs.
obese + IL-33 P < 0.0001), which was unaffected by IL-33 (for
both body weight and epididymal fat pad weights: control vs.
control + IL-33 P> 0.05, obese vs. obese + IL-33 P> 0.05, n =
8 all groups). However, spleen size was significantly larger in
control and obese mice injected with IL-33 (control vs. control +
IL-33 P < 0.001, obese vs. obese + IL-33 P < 0.0001).
Eosinophilia was confirmed using an eosinophil cationic protein
ELISA (Fig. 1D). Concentration of eosinophil cationic protein
was significantly increased in the plasma of injected control and
obese mice (control vs. control + IL-33 P < 0.0001, obese vs.
obese + IL-33 P < 0.01), more so in control-injected mice (con-
trol + IL-33 vs. obese + IL-33 P< 0.01, n = 8 all groups). Using
immunohistochemistry, we confirmed eosinophil infiltration
into mesenteric PVAT after IL-33 (Fig. 2, n = 5).
IL-33 reverses hypertension, hyperglycemia, and hyperinsu-
linemia T2D. Immediately before euthanasia, blood pressure
was recorded using the CODA tail-cuff method (Fig. 3A). High-
fat feeding resulted in significant elevations in both systolic and
diastolic blood pressures (control vs. obese P< 0.05). However,
there was no difference in either systolic or diastolic blood pres-
sure between obese + IL-33 mice and control/control + IL-33
mice (P> 0.05, n = 8 all groups), indicating a reversal of hyper-
tension in IL-33-injected obese mice. Previously, we have
shown that the DdblGATA-1 mice are hypertensive (52).












































































































































Fig. 1. IL-33 induces splenomegaly and eo-
sinophilia. Body (A), epididymal fat pads (B),
and spleen (C) weights were recorded. D:
blood was collected and centrifuged to sepa-
rate plasma. The concentration of eosinophil
cationic plasma was measured using an
ELISA kit. Data shown are means ± SE. One-
way ANOVA followed by Tukey’s post hoc
tests (all groups n = 8, **P < 0.01, ***P <
0.001, ****P < 0.0001). ANOVA, analysis
of variance; IL-33, interleukin-33.
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hypertensive compared with our control C57 mice (Fig. 3,
control vs. DdblGATA-1 + IL-33 P < 0.05, control n = 8,
DdblGATA-1 + IL-33 n = 7).
Immediately after euthanasia, blood glucose was measured
using an automatic monitor (Fig. 3B). Similar to the blood pres-
sure measurements, blood glucose concentration was signifi-
cantly increased in the obese group (control vs. obese P <
0.0001) and was reduced to a level comparable with controls in
the obese + IL-33 group (P > 0.05, n = 8 all groups).
Interestingly, blood glucose was reduced in the control + IL-33
group versus controls (P < 0.01, n = 8 all groups). The same
pattern was observed in plasma insulin measurements using an
ELISA (Fig. 3C); insulin was significantly increased in the
obese group (control vs. obese P< 0.01) and returned to control
levels in the obese + IL-33 group (P > 0.05, n = 8). The mean
insulin concentration from control mice was 51 ng/mL,
whereas in control + IL-33 mice, the mean concentration was
23 ng/mL. Although this was not statistically significant, this
may indicate at least a trend toward reduced plasma insulin in
lean controls. Nonetheless, these data indicate that IL-33 injec-
tions reversed hyperinsulinemia and hyperglycemia in obese
mice. Previously, we have shown that the DdblGATA-1 mice
exhibit hyperglycemia (52). Similarly, the DdblGATA-1 mice
injected with IL-33 were hyperglycemic compared with our
control C57 mice (Fig. 3, control vs. DdblGATA-1 + IL-33 P <
0.05, control n = 8, DdblGATA-1 + IL-33 n = 7).
PVAT exerts a reproducible anticontractile effect, which is
lost in obesity. Second-order mesenteric arteries ±PVAT were
dissected from control and obese mice. Vascular contractility
to increasing concentrations of NA was measured (Fig. 4).
Consistent with previous findings, arteries contracted signifi-
cantly less when PVAT was left intact (P < 0.01, n = 8); i.e.,
PVAT exerts an anticontractile effect on the vasculature. In
obesity, the PVAT anticontractile effect was lost and the con-
tractility of ±PVAT arteries was no different (P> 0.05, n = 8).
IL-33 injections restore PVAT function in obesity and
enhance PVAT function in health. Second-order mesenteric
arteries ±PVAT were dissected from control and obese mice
injected with IL-33 and subjected to a NA concentration
response (Fig. 5). In control + IL-33 mice, PVAT exerted a sig-
nificantly larger anticontractile effect (Fig. 5A, P < 0.0001, n =
8). In Fig. 5, C–F, we have combined data from Figs. 4A and
5A, and Figs. 4B and 5B, to compare the responses of the same
vessel types from mice with and without IL-33. Figure 5, C and
D, is a comparison of -PVAT vessels from control mice with
and without IL-33, and obese mice with and without IL-33,
respectively. There is no significant difference between these
responses (P > 0.05, n = 8 all groups). Figure 5, E and F, is a
comparison of +PVAT vessels from control mice with and with-
out IL-33, and obese mice with and without IL-33, respectively.
Using this comparison, there is a significant difference in the
responses of +PVAT arteries both within the control and obese
A B
C D
Fig. 2. Eosinophils are restored in obese PVAT by IL-33 treatment. The 12-mm sections were stained with an anti-eosinophil peroxidase antibody. A: control mouse
mesenteric PVAT. B: obese mouse mesenteric PVAT. C: mesenteric PVAT from control mice injected with IL-33. D: mesenteric PVAT from obese mice injected
with IL-33. Red arrows indicate eosinophils. Scale bar = 50 mm (representative of n = 5). IL-33, interleukin-33; PVAT, perivascular adipose tissue.
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groups with and without IL-33 (both P < 0.0001, n = 8 all
groups), suggesting that the effects of IL-33 on vascular contrac-
tility are dependent upon PVAT.
IL-33 is an acute endothelium-dependent vasodilator; how-
ever, endothelial function is impaired in obesity. Second-order
mesenteric arteries from eNOS/ and control mice with PVAT
removed were preconstricted with 1  105 M NA, before add-
ing 3 ng/mL IL-33 (example trace Fig. 6B—control vessel with
endothelium intact). To examine the contribution of the endo-
thelium, control vessels with endothelium intact and endothe-
lium removed were tested and compared with vessels from
eNOS/ mice (Fig. 6A). IL-33 induced vasorelaxation, which
was reduced in the absence of endothelium and in vessels from
eNOS/ (control + endothelium vs. control – endothelium, P<
0.001; control + endothelium vs. eNOS/, P < 0.0001; con-
trol – endothelium vs. eNOS/, P > 0.05, n = 8 all groups);
therefore, this effect must be endothelium dependent. As can be
seen in example trace Fig. 6B, the vasodilation is acute and rap-
idly decaying.
Endothelial integrity of control versus obese vessels was
compared by preconstricting vessels with 1  105 M NA,
before adding 1  107 M ACh (Fig. 6C). In obese arteries,
relaxation to ACh is impaired (P < 0.0001, n = 8), indicating
endothelial dysfunction in obesity.
Circulating adiponectin is increased in obesity and reduced
by IL-33. The concentration of adiponectin in plasma was meas-
ured using a commercially available kit (Fig. 7). Plasma adipo-
nectin was significantly increased in obesity compared with the
control group, and this was reduced back to control levels with
IL-33 (control vs. obese, P < 0.0001; control vs. control + IL-
33, P > 0.05; control vs. obese + IL-33, P > 0.05; obese vs.
obese + IL-33, P < 0.001; control and obese, n = 8; control +
IL-33, n = 5; obese + IL-33, n = 7).
IL-33 injections have no effect on PVAT function in
DdblGATA-1 mice. Previously, we have indicated that in the eo-
sinophil-deficient mouse, DdblGATA-1 mice, the PVAT anti-
contractile effect is absent. Therefore, to confirm that the
restorative/enhancing effects of IL-33 on PVAT function are
mediated via eosinophils, we injected DdblGATA-1 mice with
IL-33. Second-order mesenteric arteries ±PVAT were dissected
from DdblGATA-1 + IL-33 and subjected to a NA concentra-
tion response (Fig. 8). Consistent with our previous findings
(52), the PVAT anticontractile effect was absent, indicating that
IL-33 has had no effect (P> 0.05, n = 7).
DISCUSSION
The aim of this study was to investigate the potential for target-
ing eosinophil numbers in obesity. The main findings of this study
were that IL-33-induced eosinophilia enhanced anticontractile
function in lean mice and rescued it in obesity and this was asso-
ciated with a lowering of blood pressure and amelioration of glu-
cose intolerance. In addition, we have shown that the eosinophil
is the most likely immune cell responsible for this effect.
Consistent with previous studies, we have shown that IL-33














































































































Fig. 3. IL-33 reverses hypertension, hypergly-
cemia, and hyperinsulinemia in obesity. A:
blood pressure was recorded using the CODA
tail-cuff system in conscious restrained mice.
B: blood glucose was measured following eu-
thanasia using an automatic glucose monitor.
C: blood was collected and centrifuged to sep-
arate plasma. The concentration of insulin
was measured using an ELISA kit. Data
shown are means ± SE. One-way ANOVA
followed by Tukey’s post hoc tests (control,
obese, control + IL-33, and obese + IL-33,
n = 8; DdblGATA-1 + IL-33, n = 7; *P <
0.05, **P < 0.01, ****P < 0.0001).
ANOVA, analysis of variance; IL-33, inter-
leukin-33; NA, noradrenaline.
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plasma eosinophil cationic protein ELISA. The degree of eosin-
ophilia was increased in control mice injected with IL-33 com-
pared with obese mice injected with IL-33. In addition, using
immunohistochemistry we demonstrated that the eosinophil
numbers in PVAT, which we have previously shown to be
reduced in obesity (7), are increased following IL-33 injections.
This is consistent with another study where IL-33 was given
over a longer period and eosinophil numbers were increased in
subcutaneous depots (11). However, our data shown here are
only qualitative. The aim was to demonstrate that eosinophil
infiltration in PVAT is restored following IL-33 treatment. In
the future studies, eosinophil number in PVAT could be quanti-
fied using flow cytometry. In addition, future studies to charac-
terize the eosinophils present in PVAT (by cytokine receptor
expression) are essential.
Interestingly, although there are multiple studies reporting
reduced eosinophil numbers in mouse fat depots in models of
obesity (7, 11, 22, 32), the opposite has been found in blood from
human obese patients; i.e., circulating eosinophils are increased.
To the best of our knowledge, there is only one study, which has
looked at eosinophil numbers in obese human fat, but there are a
number of limitations to this study including the absence of dia-
betes and hypertension (34), therefore shedding no light on the
role of eosinophils in these diseases. Changes in eosinophil num-
ber following dietary intervention in mice are tissue specific (6);
therefore, we hypothesize that during the development of obesity-
associated diseases, changes in eosinophil recruitment signals and
anchoring integrins result in eosinophils moving out of fat depots
and into the bloodstream. These future studies will be vital in
understanding the mechanistic links between obesity and cardio-
vascular and metabolic diseases.
IL-33 is expressed in numerous cell types including adipo-
cytes (53), fibroblasts (42), and endothelial and epithelial cells
(35), and its receptors are expressed on basophils (47), mast
cells (3), and eosinophils (8). Therefore, to confirm that the ben-
eficial effects of IL-33 observed in this study were mediated via
eosinophils, eosinophil-deficient DdblGATA-1 mice were used.
Previously, we have shown that these mice lack a PVAT anti-
contractile effect and are hypertensive and hyperglycemic (52).
The lack of effect of IL-33 injections in this mouse model sug-
gests that the effects of IL-33 are dependent on eosinophils. In
addition to a potential direct effect of IL-33 on eosinophils, it is
likely that IL-33-induced upregulation of IL-5 also contributes
to development of eosinophilia in this model (12, 44), although
this was not measured in the current study.
Paradoxically, IL-33 expression has been shown to be
increased in the adipose tissues of severely obese humans (57).
Despite this, multiple studies have demonstrated a beneficial role
of IL-33 treatment in obesity as recently reviewed (10). Studies
in the genetically obese ob/ob mouse have shown that treatment
with recombinant IL-33 three times a week, for 3 wk, induced the
production of the Th2 cytokines including IL-5, and the polariza-
tion of adipose tissue macrophages toward an M2 phenotype
(31). Moreover, treatment reduced adiposity and reduced blood
glucose concentration in vivo. However, this study did not
describe the treatment route or exact dosage; therefore, compari-
sons with our study are difficult. Nonetheless, the results of these
studies combined with our own may indicate that exogenous IL-
33 will beneficially regulate the inflammatory process in obesity.
Interestingly, as briefly discussed, hypertrophy of adipocytes
results in local regions of hypoxia, and studies have indicated
that IL-33 expression in cultured human adipocytes is not
affected by hypoxia; however, there is a threefold increase in
the expression of IL-33 in hypoxic pre-adipocytes (53). Adipose
tissue has a limited ability to recruit new adipocytes, and it is
when this limit is reached that existing adipocytes will undergo
hypertrophy, and it is hypertrophy of adipocytes, which is asso-
ciated with increased cardiovascular risk (21). Therefore, target-
ing the differentiation of these hypoxic pre-adipocytes with
increased IL-33 may present another target by which eosinophil
number could be increased.
We are not the first to demonstrate improvements in glucose
and insulin following IL-33 treatment. Duffen et al. (11)
reported an improvement in the metabolic profile of their obese
model when IL-33 was administered over a longer period.
However, in their model, IL-33 induced gastrointestinal effects
including diarrhea, resulting in weight loss. This weight loss
may have played a role in the metabolic improvements
observed. We did not observe any gastrointestinal irregularities
in our model, which may indicate that the results of our study
are a direct effect of immune cell regulation rather than gastro-
intestinal upset.
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Fig. 4. PVAT exerts an anticontractile effect in health, which is absent in obesity. Small mesenteric arteries were isolated from control (A) and obese (B) mice and
subjected to increasing concentrations of NA. Data shown are means ± SE. Vessel contractility is expressed as a percentage of the maximum contraction evoked by
KPSS. Two-way ANOVA followed by Bonferroni post hoc tests (n = 8 both groups, *P < 0.05, **P < 0.01). ANOVA, analysis of variance; IL-33, interleukin-33;
KPSS, [K+]PSS; NA, noradrenaline; PVAT, perivascular adipose tissue.
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This is the first study to report a beneficial effect of IL-33 on
blood pressure and the role of PVAT role in regulating vascular
tone. Moreover, the effects of IL-33 were not limited to obesity,
and these studies revealed a beneficial effect of IL-33 on blood
glucose concentrations in lean mice. The mechanism by which
IL-33-induced eosinophilia confers metabolic benefits in obesity
may involve the recent finding that eosinophils produce cate-
cholamines (52). Previously, we have demonstrated that the
anticontractile effect is mediated via sympathetic nerve-derived
NA, which activates adipocyte b3-adrenoceptors, stimulating
the release of the vasodilator adiponectin (43). In addition, we
have found that eosinophils directly modulate the PVAT anticon-
tractile function via a b3-adrenoceptor and adiponectin-depend-
ent mechanism (52). Therefore, catecholamines from eosinophils
likely feed into the sympathetic nerve-mediated mechanism and
promote vasodilation. This hypothesis is supported by our previ-
ous studies in the DdblGATA-1 mouse. As already discussed, the
PVAT anticontractile effect is absent in these mice, but could be
restored using eosinophil reconstitution (51). This restored
PVAT effect could be reduced using either a b3-adrenoceptor an-
tagonist or a blocking peptide for adiponectin receptor 1. In obe-
sity, PVAT function is lost, and it is widely accepted that
autonomic dysfunction occurs in obesity (29, 45). Therefore, eo-
sinophils may provide an alternative source of catecholamines to
regulate PVAT function.
Plasma adiponectin levels were high in obese mice and were
restored to normal levels following IL-33 injection. It is likely
that increased plasma adiponectin in obesity is a result of
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Fig. 5. IL-33 treatment enhances PVAT function and restores the anticontractile effect in obesity. Small mesenteric arteries were isolated from control (A) and obese
(B) mice injected with IL-33 and subjected to increasing concentrations of NA. C–F: data from Fig. 4, A and B, have been combined with data from Fig. 5, A and B,
to compare responses of ±PVAT vessels from mice with and without IL-33 treatment (C and D: -PVAT vessels from control and obese mice, respectively, E and F:
+PVAT vessels from control and obese mice, respectively). Data shown are means ± SE. Vessel contractility is expressed as a percentage of the maximum contrac-
tion evoked by KPSS. Two-way ANOVA followed by Bonferroni post hoc tests (n = 8 all groups, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
ANOVA, analysis of variance; IL-33, interleukin-33; KPSS, [K+]PSS; PVAT, perivascular adipose tissue.
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impaired uptake and/or clearance. Adiponectin binds to both
AdipoR1 and AdipoR2 receptors to mediate its pleiotropic bio-
logical actions, and studies have reported decreased adiponectin
receptor expression in obese mice (48) and decreased AdipoR1/
R2 expression in obese mice are directly related to insulin resist-
ance and elevated blood glucose (39). Furthermore, another
study has reported a prolonged clearance rate of adiponectin
by the liver in obese mice and a dramatically increased half-
life (20). Therefore, if adiponectin clearance and metabolism
is impaired in obesity, this may result in an accumulation in
the blood. As such, further investigations into AdipoR1/
AdipoR2 expression and adiponectin clearance in healthy
and obese mice are required to understand these results.
Nonetheless, IL-33 injections reduced adiponectin levels in
obesity, indicating a restorative effect of IL-33 on adiponec-
tin levels in obesity.
Interestingly, in this study, to our knowledge, we report for
the first time that IL-33 is an acute vasodilator in small mesen-
teric arteries. IL-33 was tested in vessels with endothelium
intact, and endothelium removed following mechanical disrup-
tion, which indicated that the vasodilator effect is endothelium
dependent. However, this method of endothelium removal is
limited; therefore, we further tested IL-33 in vessels from
eNOS/ mice; without eNOS, there can be no endothelium-de-
pendent vasorelaxation, and indeed, IL-33 had very little effect
on arteries from these mice. As such, IL-33 exerts a direct effect
on the vasculature, which is mediated by nitric oxide in the en-
dothelium. However, this effect was rapidly decaying and there-
fore is unlikely to contribute to the changes in blood pressure
observed in this study, particularly given that the last dosage of
IL-33 was given 24 h before measuring blood pressure.
Moreover, this effect is endothelium dependent, and we have
demonstrated that the endothelium is impaired in our obese
model. Therefore, the results of this study are not mediated by a
direct effect of IL-33 on the vasculature.
Some studies have indicated that beneficial role of eosino-
phils is via promoting anti-inflammatory M2 macrophage
polarization in adipose tissue (54, 55). Macrophages repre-
sent the largest proportion of immune cells in PVAT, and
pro-inflammatory M1 macrophages are increased in number
in obesity (49, 50). In addition, M1 macrophages are associ-
ated with the development of insulin resistance and hyper-
tension (23, 37, 41), whereas M2 macrophages play a role in
adipose tissue homeostasis, in particular through their role
in adipocyte turnover and lipid buffering (16, 27). Studies
on M2 macrophages as a source of catecholamines are con-
flicting, with some suggesting a role for M2-derived cate-
cholamines in adaptive thermogenesis (38), and others
disputing the ability of M2 macrophages to synthesize cate-












































































































































Fig. 6. IL-33 stimulates a rapidly decaying
endothelium-dependent vasorelaxation. A:
small mesenteric arteries were isolated from
control and eNOS/ mice. To examine the
role of endothelium, it was mechanically
removed from some control arteries. All
arteries were preconstricted with NA (1 
105 M) before applying a single dose of IL-
33 (3 ng/mL). B: example trace for a control
artery with endothelium intact. C: small mes-
enteric arteries were isolated from control and
obese mice. To test endothelial integrity, ves-
sels are preconstricted with NA (1  105
M), before adding ACh (1  107 M). Data
shown are means ± SE. A: one-way ANOVA
followed by Bonferroni post hoc tests. C:
unpaired t test (n = 8 all groups, **P < 0.01,
***P< 0.001, ****P< 0.0001). Ach, acetyl-
choline; ANOVA, analysis of variance;
eNOS/, endothelial nitric oxide synthase
knockout mice; IL-33, interleukin-33; NA,
noradrenaline.
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the subtle differences between macrophage subpopulations
and make clearly classifying macrophages difficult and per-
haps currently unreliable (33).
Although the effectiveness of IL-33 injections in treating
hypertension and T2D is promising, the resultant splenomegaly
does significantly limit its therapeutic potential, as an enlarged
spleen is susceptible to rupture. Of note, the splenomegaly in
this study is consistent with previous studies of IL-33-injected
mice, in which the enlarged spleens were attributed to increased
numbers of eosinophils, mononuclear cells, and plasma cells
(44). However, we did not conduct any long-term studies to
determine how long the beneficial effects of IL-33 (or the effects
on spleen size) persist following five consecutive daily injec-
tions. It is possible that alterations to the dosage, or frequency of
injections, could induce beneficial effects in hypertension and
T2D, without significant effects on the spleen. Indeed, another
study using IL-33 treatment three times a week for 3 wk did not
report any effects on the spleen (31). In addition, as previously
discussed another study reported significant gastrointestinal
effects (11), which reinforces the potential harmful effects of an
intense forced immune response. Nonetheless, these studies
open an exciting avenue to be explored, whereby targeting eo-
sinophil number presents a novel and highly useful therapeutic
target in obesity.
Limitations and future directions. The results of this study
demonstrate a clear effect of IL-33 on blood pressure, blood glu-
cose, and plasma insulin homeostasis. However, the mechanism
of these effects remains unclear. As discussed above, we believe
that eosinophils will factor into the sympathetic nerve-mediated
anticontractile effect which we have previously described (43).
Therefore, future studies are needed to investigate the levels of
catecholamines, b3-adrenoceptors, and adiponectin receptors in
our model. In addition, eosinophil numbers and their phenotype
in multiple tissues within our model need to be fully character-
ized to determine whether the effects of obesity and IL-33 on
eosinophil number are tissue dependent and whether it is a cer-
tain type of eosinophil, which is required to mediate beneficial
effects in obesity. Furthermore, future studies are needed to fur-
ther characterize the effects of IL-33 on the obese phenotype,
including using radiotelemetry to measure blood pressure, glu-
cose tolerance testing, and characterization of changes to other
circulating lipids and adipokines (25).
In summary, IL-33 induced eosinophilia in both lean and
obese mice and restored PVAT function in obesity and
enhanced the anticontractile function of PVAT in healthy ani-
mals. In addition, hypertension, blood glucose, and plasma insu-
lin were normalized in obese mice. These data suggest that
targeting the eosinophil numbers in PVAT presents a novel
approach by which to influence cardiovascular and metabolic
diseases in obesity.
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Fig. 7. Plasma adiponectin is increased in obesity and returned to control
levels with IL-33. Blood was collected and centrifuged to separate plasma.
The concentration of adiponectin was measured using an ELISA kit. Data
shown are means ± SE. One-way ANOVA followed by Tukey’s post hoc
tests (control and obese, n = 8; control + IL-33, n = 5; obese + IL-33, n = 7;
***P < 0.001, ****P < 0.0001). ANOVA, analysis of variance; IL-33,
interleukin-33.



















Fig. 8. The PVAT anticontractile effect is absent in eosinophil-deficient mice
injected with IL-33. Small mesenteric arteries were isolated from
DdblGATA-1 mice injected with IL-33 and subjected to increasing concen-
trations of NA. Data shown are means ± SE. Vessel contractility is expressed
as a percentage of the maximum contraction evoked by KPSS. Two-way
ANOVA followed by Bonferroni post hoc tests (n = 7). ANOVA, analysis of
variance; IL-33, interleukin-33; KPSS, [K+]PSS; NA, noradrenaline; PVAT,
perivascular adipose tissue.
EFFECTS OF IL-33 ON OBESE PVAT H1395
AJP-Heart Circ Physiol  doi:10.1152/ajpheart.00491.2020  www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart at Univ of Salford Lib (146.087.136.100) on December 11, 2020.
REFERENCES
1. Aghamohammadzadeh R, Heagerty AM. Obesity-related hypertension:
epidemiology, pathophysiology, treatments, and the contribution of perivas-
cular adipose tissue. Ann Med 44, Suppl 1: S74–S84, 2012. doi:10.3109/
07853890.2012.663928.
2. Aghamohammadzadeh R, Withers S, Lynch F, Greenstein A, Malik R,
Heagerty A. Perivascular adipose tissue from human systemic and coronary
vessels: the emergence of a new pharmacotherapeutic target. Br J
Pharmacol 165: 670–682, 2012. doi:10.1111/j.1476-5381.2011.01479.x.
3. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The
ST2 ligand IL-33 potently activates and drives maturation of human mast
cells. J Immunol 179: 2051–2054, 2007. doi:10.4049/jimmunol.179.4.2051.
4. Bjørndal B, Burri L, Staalesen V, Skorve J, Berge RK. Different adipose
depots: their role in the development of metabolic syndrome and mitochon-
drial response to hypolipidemic agents. J Obes 2011: 490650, 2011. doi:10.
1155/2011/490650.
5. Blackwell AD, Trumble BC,Maldonado Suarez I, Stieglitz J, Beheim B,
Snodgrass JJ,Kaplan H,Gurven M. Immune function in Amazonian hor-
ticulturalists. Ann Hum Biol 43: 382–396, 2016. doi:10.1080/03014460.
2016.1189963.
6. Bolus WR, Kennedy AJ,Hasty AH. Obesity-induced reduction of adipose
eosinophils is reversed with low-calorie dietary intervention. Physiol Rep 6:
e13919, 2018. doi:10.14814/phy2.13919.
7. Bussey CE, Withers SB, Aldous RG, Edwards G, Heagerty AM.
Obesity-related perivascular adipose tissue damage is reversed by sustained
weight loss in the rat. Arterioscler Thromb Vasc Biol 36: 1377–1385, 2016.
doi:10.1161/ATVBAHA.116.307210.
8. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 fam-
ily cytokine, IL-33, potently activates human eosinophils. J Allergy Clin
Immunol 121: 1484–1490, 2008. doi:10.1016/j.jaci.2008.04.005.
9. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an en-
docrine organ. Arch Med Sci 9: 191–200, 2013. doi:10.5114/aoms.
2013.33181.
10. de Oliveira MFA, Talvani A, Rocha-Vieira E. IL-33 in obesity: where do
we go from here? Inflamm Res 68: 185–194, 2019. doi:10.1007/s00011-
019-01214-2.
11. Duffen J, Zhang M, Masek-Hammerman K, Nunez A, Brennan A,
Jones JEC, Morin J, Nocka K, Kasaian M. Modulation of the IL-33/IL-
13 axis in obesity by IL-13Ra2. J Immunol 200: 1347–1359, 2018.
doi:10.4049/jimmunol.1701256.
12. Dyer KD, Percopo CM, Rosenberg HF. IL-33 promotes eosinophilia in
vivo and antagonizes IL-5-dependent eosinophil hematopoiesis ex vivo.
Immunol Lett 150: 41–47, 2013. doi:10.1016/j.imlet.2012.12.002.
13. Feng M, Whitesall S, Zhang Y, Beibel M, D’Alecy L, DiPetrillo K.
Validation of volume-pressure recording tail-cuff blood pressure measure-
ments. Am J Hypertens 21: 1288–1291, 2008. doi:10.1038/ajh.2008.301.
14. Finlay CM, Walsh KP, Mills KH. Induction of regulatory cells by hel-
minth parasites: exploitation for the treatment of inflammatory diseases.
Immunol Rev 259: 206–230, 2014. doi:10.1111/imr.12164.
15. Fischer K, Ruiz HH, Jhun K, Finan B, Oberlin DJ, van der Heide V,
Kalinovich AV, Petrovic N, Wolf Y, Clemmensen C, Shin AC,
Divanovic S, Brombacher F, Glasmacher E, Keipert S, Jastroch M,
Nagler J, Schramm KW, Medrikova D, Collden G, Woods SC, Herzig
S, Homann D, Jung S, Nedergaard J, Cannon B, Tsch€op MH, M€uller
TD, Buettner C. Alternatively activated macrophages do not synthesize
catecholamines or contribute to adipose tissue adaptive thermogenesis. Nat
Med 23: 623–630, 2017. doi:10.1038/nm.4316.
16. Fischer-Posovszky P,Wang QA, Asterholm IW, Rutkowski JM, Scherer
PE. Targeted deletion of adipocytes by apoptosis leads to adipose tissue
recruitment of alternatively activated M2 macrophages. Endocrinology 152:
3074–3081, 2011. doi:10.1210/en.2011-1031.
17. Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, Lee RM.
Perivascular adipose tissue promotes vasoconstriction: the role of superoxide
anion. Cardiovasc Res 71: 363–373, 2006. doi:10.1016/j.cardiores.2006.
03.013.
18. Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, Konings
E, Jocken JW,Cajlakovic M,Ribitsch V,Clement K, Blaak EE. Increased
adipose tissue oxygen tension in obese compared with lean men is accompa-
nied by insulin resistance, impaired adipose tissue capillarization, and inflam-
mation. Circulation 124: 67–76, 2011. doi:10.1161/CIRCULATIONAHA.
111.027813.
19. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O,
Jeziorska M, Laing I, Yates AP, Pemberton PW, Malik RA, Heagerty
AM. Local inflammation and hypoxia abolish the protective anticontractile
properties of perivascular fat in obese patients. Circulation 119: 1661–1670,
2009. doi:10.1161/CIRCULATIONAHA.108.821181.
20. Halberg N, Schraw TD, Wang ZV, Kim JY, Yi J, Hamilton MP, Luby-
Phelps K, Scherer PE. Systemic fate of the adipocyte-derived factor adipo-
nectin. Diabetes 58: 1961–1970, 2009. doi:10.2337/db08-1750.
21. Hammarstedt A, Gogg S, Hedjazifar S, Nerstedt A, Smith U. Impaired
adipogenesis and dysfunctional adipose tissue in human hypertrophic obe-
sity. Physiol Rev 98: 1911–1941, 2018. doi:10.1152/physrev.00034.2017.
22. Hams E, Locksley RM, McKenzie AN, Fallon PG. Cutting edge: IL-25
elicits innate lymphoid type 2 and type II NKT cells that regulate obesity in
mice. J Immunol 191: 5349–5353, 2013. doi:10.4049/jimmunol.1301176.
23. Harwani SC, Chapleau MW, Legge KL, Ballas ZK, Abboud FM.
Neurohormonal modulation of the innate immune system is proinflam-
matory in the prehypertensive spontaneously hypertensive rat, a genetic
model of essential hypertension. Circ Res 111: 1190–1197, 2012.
doi:10.1161/CIRCRESAHA.112.277475.
24. Huang Cao ZF, Stoffel E, Cohen P. Role of perivascular adipose tissue in
vascular physiology and pathology. Hypertension 69: 770–777, 2017.
doi:10.1161/HYPERTENSIONAHA.116.08451.
25. Johnston LK, Bryce PJ. Understanding interleukin 33 and its roles in eo-
sinophil development. Front Med (Lausanne) 4: 51, 2017. doi:10.3389/
fmed.2017.00051.
26. Kaplan H, Thompson RC, Trumble BC, Wann LS, Allam AH, Beheim
B, Frohlich B, Sutherland ML, Sutherland JD, Stieglitz J, Rodriguez
DE, Michalik DE, Rowan CJ, Lombardi GP, Bedi R, Garcia AR, Min
JK, Narula J, Finch CE, Gurven M, Thomas GS. Coronary atherosclero-
sis in indigenous South American Tsimane: a cross-sectional cohort study.
Lancet 389: 1730–1739, 2017. doi:10.1016/S0140-6736(17)30752-3.
27. Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R,
Ferrante AW Jr. Weight loss and lipolysis promote a dynamic immune
response in murine adipose tissue. J Clin Invest 120: 3466–3479, 2010.
doi:10.1172/JCI42845.
28. Madec S, Chiarugi M, Santini E, Rossi C, Miccoli P, Ferrannini E,
Solini A. Pattern of expression of inflammatory markers in adipose tissue of
untreated hypertensive patients. J Hypertens 28: 1459–1465, 2010.
doi:10.1097/HJH.0b013e3283388871.
29. Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H.
Sympathetic overactivity in hypertension and cardiovascular disease. Curr
Vasc Pharmacol 12: 4–15, 2014. doi:10.2174/15701611113119990140.
30. Mehta P, Furuta GT. Eosinophils in gastrointestinal disorders: eosino-
philic gastrointestinal diseases, celiac disease, inflammatory bowel diseases,
and parasitic infections. Immunol Allergy Clin North Am 35: 413–437,
2015. doi:10.1016/j.iac.2015.04.003.
31. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM,
McKenzie AN, Xu D, Sattar N, McInnes IB, Liew FY. Interleukin-33
induces protective effects in adipose tissue inflammation during obesity in
mice. Circ Res 107: 650–658, 2010. doi:10.1161/CIRCRESAHA.110.
218867.
32. Molofsky AB, Nussbaum JC, Liang HE, Van Dyken SJ, Cheng LE,
Mohapatra A, Chawla A, Locksley RM. Innate lymphoid type 2 cells sus-
tain visceral adipose tissue eosinophils and alternatively activated macro-
phages. J Exp Med 210: 535–549, 2013. doi:10.1084/jem.20121964.
33. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage acti-
vation. Nat Rev Immunol 8: 958–969, 2008 [Erratum in Nat Rev Immunol
10: 460, 2010]. doi:10.1038/nri2448.
34. Moussa K,Gurung P, Adams-Huet B, Devaraj S, Jialal I. Increased eosin-
ophils in adipose tissue of metabolic syndrome. J Diabetes Complications 33:
535–538, 2019. doi:10.1016/j.jdiacomp.2019.05.010.
35. Moussion C, Ortega N,Girard JP. The IL-1-like cytokine IL-33 is consti-
tutively expressed in the nucleus of endothelial cells and epithelial cells in
vivo: a novel ‘alarmin’? PLoS One 3: e3331, 2008. doi:10.1371/journal.
pone.0003331.
36. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol
Rev 70: 921–961, 1990. doi:10.1152/physrev.1990.70.4.921.
37. Ndisang JF,MishraM. The heme oxygenase system selectively suppresses
the proinflammatory macrophage m1 phenotype and potentiates insulin sig-
naling in spontaneously hypertensive rats. Am J Hypertens 26: 1123–1131,
2013. doi:10.1093/ajh/hpt082.
38. Nguyen KD, Qiu Y, Cui X, Goh YP, Mwangi J, David T, Mukundan L,
Brombacher F, Locksley RM, Chawla A. Alternatively activated macro-
phages produce catecholamines to sustain adaptive thermogenesis. Nature
480: 104–108, 2011. doi:10.1038/nature10653.
H1396 EFFECTS OF IL-33 ON OBESE PVAT
AJP-Heart Circ Physiol  doi:10.1152/ajpheart.00491.2020  www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart at Univ of Salford Lib (146.087.136.100) on December 11, 2020.
39. Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G,
Costagliola C, Bianco A, Daniele A. New insight into adiponectin role in
obesity and obesity-related diseases. BioMed Res Int 2014: 658913, 2014.
doi:10.1155/2014/658913.
40. Nosalski R,Guzik TJ. Perivascular adipose tissue inflammation in vascular
disease. Br J Pharmacol 174: 3496–3513, 2017. doi:10.1111/bph.13705.
41. Osborn O, Olefsky JM. The cellular and signaling networks linking the
immune system and metabolism in disease. Nat Med 18: 363–374, 2012.
doi:10.1038/nm.2627.
42. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee
RT. IL-33 and ST2 comprise a critical biomechanically induced and cardio-
protective signaling system. J Clin Invest 117: 1538–1549, 2007.
doi:10.1172/JCI30634.
43. Saxton SN, Ryding KE, Aldous RG, Withers SB, Ohanian J, Heagerty
AM. Role of sympathetic nerves and adipocyte catecholamine uptake in the
vasorelaxant function of perivascular adipose tissue. Arterioscler Thromb
Vasc Biol 38: 880–891, 2018. doi:10.1161/ATVBAHA.118.310777.
44. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan
TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF,
Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1
receptor-related protein ST2 and induces T helper type 2-associated cyto-
kines. Immunity 23: 479–490, 2005. doi:10.1016/j.immuni.2005.09.015.
45. Smith MM, Minson CT. Obesity and adipokines: effects on sympathetic
overactivity. J Physiol 590: 1787–1801, 2012. doi:10.1113/jphysiol.2011.
221036.
46. Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic
smooth muscle responsiveness. Clin Exp Hypertens A 13: 277–296, 1991.
doi:10.3109/10641969109042063.
47. Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A,
Nakae S, Matsushima K, Ohta K, Yamamoto K, Yamaguchi M. An IL-
1 cytokine member, IL-33, induces human basophil activation via its ST2
receptor. J Immunol 181: 5981–5989, 2008. doi:10.4049/jimmunol.181.
9.5981.
48. Tsuchida A, Yamauchi T, Ito Y, Hada Y,Maki T, Takekawa S, Kamon
J, Kobayashi M, Suzuki R, Hara K, Kubota N, Terauchi Y, Froguel P,
Nakae J, Kasuga M, Accili D, Tobe K, Ueki K, Nagai R, Kadowaki T.
Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors
and adiponectin sensitivity. J Biol Chem 279: 30817–30822, 2004.
doi:10.1074/jbc.M402367200.
49. van Stijn CM, Kim J, Lusis AJ, Barish GD, Tangirala RK. Macrophage
polarization phenotype regulates adiponectin receptor expression and adipo-
nectin anti-inflammatory response. FASEB J 29: 636–649, 2015.
doi:10.1096/fj.14-253831.
50. Weisberg SP,McCann D, Desai M, RosenbaumM, Leibel RL, Ferrante
AW Jr. Obesity is associated with macrophage accumulation in adipose tis-
sue. J Clin Invest 112: 1796–1808, 2003. doi:10.1172/JCI200319246.
51. Withers SB, Bussey CE, Saxton SN, Melrose HM, Watkins AE,
Heagerty AM.Mechanisms of adiponectin-associated perivascular function
in vascular disease. Arterioscler Thromb Vasc Biol 34: 1637–1642, 2014.
doi:10.1161/ATVBAHA.114.303031.
52. Withers SB, Forman R, Meza-Perez S, Sorobetea D, Sitnik K,
Hopwood T, Lawrence CB, Agace WW, Else KJ, Heagerty AM,
Svensson-Frej M, Cruickshank SM. Eosinophils are key regulators of
perivascular adipose tissue and vascular functionality. Sci Rep 7: 44571,
2017. doi:10.1038/srep44571.
53. Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1
gene family member, is expressed in human adipocytes. Biochem Biophys
Res Commun 384: 105–109, 2009. doi:10.1016/j.bbrc.2009.04.081.
54. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA,
Bando JK, Chawla A, Locksley RM. Eosinophils sustain adipose alterna-
tively activated macrophages associated with glucose homeostasis. Science
332: 243–247, 2011. doi:10.1126/science.1201475.
55. Xu J, Wang J, Shao C, Zeng X, Sun L, Kong H, Xie W, Wang H. New
dynamic viewing of mast cells in pulmonary arterial hypertension (PAH):
contributors or outsiders to cardiovascular remodeling. J Thorac Dis 10:
3016–3026, 2018. doi:10.21037/jtd.2018.05.59.
56. Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from peri-
vascular fat: a mechanism linking insulin resistance to vascular disease.
Lancet 365: 1817–1820, 2005. doi:10.1016/S0140-6736(05)66585-3.
57. ZeydaM,Wernly B, Demyanets S,Kaun C,H€ammerle M,Hantusch B,
Schranz M, Neuhofer A, Itariu BK, Keck M, Prager G, Wojta J,
Stulnig TM. Severe obesity increases adipose tissue expression of interleu-
kin-33 and its receptor ST2, both predominantly detectable in endothelial
cells of human adipose tissue. Int J Obes 37: 658–665, 2013. doi:10.1038/
ijo.2012.118.
EFFECTS OF IL-33 ON OBESE PVAT H1397
AJP-Heart Circ Physiol  doi:10.1152/ajpheart.00491.2020  www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart at Univ of Salford Lib (146.087.136.100) on December 11, 2020.
